Amylyx Pharmaceuticals Files 8-K on Security Holder Vote Matters
Ticker: AMLX · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1658551
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Amylyx is having a shareholder vote meeting soon.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of its security holders. The filing does not disclose specific details about the matters to be voted on or any associated financial implications.
Why It Matters
This filing indicates that Amylyx Pharmaceuticals is convening a meeting where security holders will vote on important company matters, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information that directly impacts the company's financial health or operations.
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of Report
FAQ
What specific matters will be submitted for a vote by Amylyx Pharmaceuticals' security holders?
The filing does not specify the exact matters to be submitted for a vote, only that such matters will be presented.
When is the meeting of security holders scheduled to take place?
The filing does not provide the date of the meeting, only that matters are being submitted for a vote.
Are there any financial implications associated with the matters to be voted on?
The filing does not disclose any financial implications related to the matters to be voted on.
What is the purpose of submitting these matters to a vote of security holders?
The purpose is to allow security holders to vote on company matters as required by corporate governance or specific events, though the exact reason is not detailed.
Does this filing relate to any recent corporate actions or changes at Amylyx Pharmaceuticals?
The filing indicates a submission of matters to a vote, which could be related to corporate actions, but the specific nature of these actions is not detailed in this report.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 14.4 · Accepted 2024-06-06 16:07:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
Filing Documents
- d844544d8k.htm (8-K) — 34KB
- 0001193125-24-156050.txt ( ) — 150KB
- amlx-20240606.xsd (EX-101.SCH) — 3KB
- amlx-20240606_lab.xml (EX-101.LAB) — 17KB
- amlx-20240606_pre.xml (EX-101.PRE) — 11KB
- d844544d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: June 6, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer